gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 11, 2002, Pages 3418-3421

  Dridi, Larbi ^a   Tankovic, Jacques ^a   Burghoffer, Béatrice ^a   Barbut, Frédéric ^a   Petit, Jean Claude ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE IV; ETHIDIUM BROMIDE; GENE PRODUCT; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLOOD GROUP TYPING; CLOSTRIDIUM DIFFICILE; CROSS RESISTANCE; DNA DNA HYBRIDIZATION; FRANCE; GENE AMPLIFICATION; GENE MUTATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROTYPE;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; CLOSTRIDIUM DIFFICILE; DNA GYRASE; DNA, FUNGAL; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FLUOROQUINOLONES; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; QUINOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0036840972     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.11.3418-3421.2002     Document Type: Article

References (26)

1. Ackermann, G., Y. J. Tang, A. C. Rodloff, J. Silva, Jr., S. H. Cohen, and P. Heisig. 2001. In vitro activity of sitafloxacin against Clostridium difficile. J. Antimicrob. Chemother. 47:722-724.
2. Ackermann, G., Y. J. Tang, R. Kueper, P. Heisig, A. C. Rodloff, J. Silva, Jr., and S. H. Cohen. 2001. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob. Agents Chemother. 45:2348-2353.
3. Alonso, R., T. Pelaez, M. J. Gonzalez-Abad, L. Alcala, P. Munoz, M. Rodriguez.Creixems, and F. Bouza. 2001. In vitro activity of new quinolones against Clostridium difficile. J. Antimicrob. Chemother. 47:195-197.
4. Bachoual, R., J. Tankovic, and C. J. Soussy. 1998. Analysis of the mutations involved in fluoroquinolone resistance of in vivo and in vitro mutants of Escherichia coli. Microb. Drug Resist. 4:271-275.
5. Bachoual, R., L. Dubreuil, C. J. Soussy, and J. Tankovic. 2000. Role of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin. Antimicrob. Agents Chemother. 44:1842-1845.
6. Bachoual, R., S. Ouabdesselam, F. Mory, C. Lascols, C. J. Soussy, and J. Tankovic. 2001. Single or double mutational alterations of gyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli. Microb. Drug Resist. 7:257-261.
7. Barbut, F., D. Decre, B. Burghoffer, D. Lesage, F. Delisle, V. Lalande, M. Delmee, V. Avesani, N. Sano, C. Coudert, and J.-C. Petit. 1999. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob. Agents Chemother. 43:2607-2611.
8. Bast, D. J., D. E. Low, C. I. Duncan, L. Kilburn, L. A. Mandell, R. J. Davidson, and J. C. de Azavedo. 2000. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob. Agents Chemother. 44:3049-3054.
9. Bidet, P., V. Lalande, B. Salauze, B. Burghoffer, V. Avesani, M. Delmée, A. Rossier, F. Barbut, and J. C. Petit. 2000. Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile. J. Clin. Microbiol. 38:2484-2487.
10. Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, C. E. Barry 3rd, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, B. G. Barrell, et al. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544.
11. Comité de l'Antibiogramme de la Société Française de Microbiologie. 2002. Communiqué 2002. Société Française de Microbiologie, Paris, France.
12. Delmée, M., C. Depitre, G. Corthier, A. Ahoyo, and V. Avesani. 1993. Use of an enzyme-linked immunoassay for Clostridium difficile serogrouping. J. Clin. Microbiol. 31:2526-2528.
13. Edlund, C., S. Sabouri, and C. E. Nord. 1998. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 17:193-195.
14. Fournier, B., and D. C. Hooper. 1998. Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity. Antimicrob. Agents Chemother. 42:2109-2112.
15. Fraser, C. M., S. J. Norris, G. M. Weinstock, 0. White, G. G. Sutton, R. Dodson, M. Gwinn, E. K. Hickey, R. Clayton, K. A. Ketchum, E. Sodergren, J. M. Hardham, M. P. McLeod, S. Salzberg, J. Peterson, H. Khalak, D. Richardson, J. K. Howell, M. Chidambaram, T. Utterback, L. McDonald, P. Artiach, C. Bowman, M. D. Cotton, J. C. Venter, et al. 1998. Complete genome sequence of Treponema pallidum, the syphilis spirochete. Science 281:375-388.
16. Griggs, D. J., K. Gensberg, and L. J. V. Piddock. 1996. Mutations in gyrA gene of quinolone-resistant Salmonella serotypes isolated from humans and animals. Antimicrob. Agents Chemother. 40:1009-1013.
17. , Hoogkamp-Korstanje, J. A. A., and J. Roelofs-Willemse. 2000. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates. J. Antimicrob. Chemother. 45:31-39.
18. Hooper, D. C. 1999. Mechanisms of fluoroquinolone resistance. Drug. Resist. Updates 2:38-55.
19. Kelly, C. P., C. Pothoulakis, and J. T. LaMont. 1994. Clostridium difficile colitis. N. Engl. J. Med. 330:257-262.
20. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1881-1888.
21. Tankovic, J., B. Périchon, J. Duval, and P. Courvalin. 1996. Contribution of mutations in the gyrA and parC genes to fluoroquinolone resistance of in vivo and in vitro mutants of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2505-2510.
22. Tomb, J. F., O. White, A. R. Kerlavage, R. A. Clayton, G. G. Sutton, R. D. Fleischmann, K. A. Ketchum, H. P. Klenk, S. Gill, B. A. Dougherty, K. Nelson, J. Quackenbush, I. Zhou, E. F. Kirkness, S. Peterson, B. Loftus, D. Richardson, R. Dodson, H. G. Khalak, A. Glodek, K. Mc Kenney, L. M. Fitzegerald, N. Lee, M. D. Adams, J. C. Venter, et al. 1997. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388:539-547.
23. Walters, B. A. J., R. Roberts, R. Stafford, and E. Seneviratne. 1983. Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy. Gut 24:206-212.
24. Wilcox, M. H. 1998. Treatment of Clostridium difficile infection. J. Antimicrob. Chemother. 41(Suppl. C):41-46.
25. Wilcox, M. H., W. Fawley, J. Freeman, and J. Brayson. 2000. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. J. Antimicrob. Chemother. 46:551-556.
26. Woodcock, J. M., J. M. Andrews, F. J. Boswell, N. P. Brenwald, and R. Wise. 1997. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. 41:101-106.